Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine augmentation of PE for PTSD and mTBI
NCT04280965Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quetiapine in post-traumatic stress disorder (PTSD), sponsored by UT Health San Antonio. Primary endpoint: Percentage compliance in completing PE sessions at 1.5 years. Started Feb 2019; status: completed.
02
Drugs
quetiapine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04280965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280965.